Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHG regimen for high-risk myelodysplastic syndrome or MDS-transformed acute myeloid leukemia
ChiCTR-ONC-11001501Phase 4Completed
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Mar 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cytarabine, homoharringtonine and filgrastim in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Complete remission rate. Started Mar 2006; status: completed.
02
Drugs
cytarabinehomoharringtoninefilgrastim
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-ONC-11001501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-11001501.